“Swing Factors” Will Heavily Influence GSK Growth In ’08, Chief Exec Garnier Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Outcome of a plan to jumpstart sales of Avandia and FDA approval of Cervarix are two key issues that will impact GSK in the new year.
You may also be interested in...
GSK Will Answer FDA “Complete Response” Letter For Cervarix In Second Quarter
Advisory committee review of the human papilloma virus vaccine expected, CEO Garnier says during year-end earnings call.
GSK Will Answer FDA “Complete Response” Letter For Cervarix In Second Quarter
Advisory committee review of the human papilloma virus vaccine expected, CEO Garnier says during year-end earnings call.
GSK Receives “Complete Response” Letter For Cervarix BLA
Drug maker will respond to FDA “as soon as possible” to answer outstanding questions related to the HPV vaccine.